Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $120,500.00 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $4.82, for a total value of $120,500.00. Following the completion of the sale, the chief executive officer owned 652,317 shares in the company, valued at approximately $3,144,167.94. The trade was a 3.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aquestive Therapeutics Stock Performance

Shares of AQST opened at $4.61 on Friday. The stock has a 50 day moving average price of $4.44 and a 200 day moving average price of $4.28. Aquestive Therapeutics, Inc. has a one year low of $2.93 and a one year high of $7.55. The stock has a market capitalization of $578.60 million, a price-to-earnings ratio of -7.09 and a beta of 1.48.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $13.82 million for the quarter, compared to the consensus estimate of $11.42 million. On average, analysts predict that Aquestive Therapeutics, Inc. will post -0.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AQST. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Monday, August 24th. Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price target on shares of Aquestive Therapeutics in a research report on Thursday, September 10th. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AQST. ADAR1 Capital Management LLC raised its holdings in Aquestive Therapeutics by 103.9% in the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after acquiring an additional 264,000 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new position in Aquestive Therapeutics during the 1st quarter worth approximately $42,000. Legal & General Group Plc purchased a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at approximately $44,000. Wealthfront Advisers LLC acquired a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at $44,000. Finally, Keating Financial Advisory Services Inc. acquired a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at $52,000. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines delivered through its PharmFilm technology. The company’s dissolvable oral-film platform is designed to provide alternatives to conventional tablets, capsules and injectable therapies, with potential benefits for patients who have difficulty swallowing or require rapid, convenient administration.

Aquestive’s commercial products include Exservan, an oral film formulation of riluzole for people with amyotrophic lateral sclerosis; Libervant, a buccal film formulation of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity; and Sympazan, an oral film formulation of clonazepam for the treatment of seizures associated with Lennox-Gastaut syndrome.